| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |